Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction

Relation of Coronary Microvascular Dysfunction in Hypertrophic Cardiomyopathy to Contractile Dysfunction Independent from Myocardial Injury

(2011) Stefan A.J. Timmer et al.   AMERICAN JOURNAL OF CARDIOLOGY

Metabolic Modulator Perhexiline Corrects Energy Deficiency and Improves Exercise Capacity in Symptomatic Hypertrophic Cardiomyopathy

(2010) Khalid Abozguia et al.   CIRCULATION

Determinants of myocardial energetics and efficiency in symptomatic hypertrophic cardiomyopathy

(2010) Stefan A. J. Timmer et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Reappraisal of a single-tissue compartment model for estimation of myocardial oxygen consumption by [11C]acetate PET

(2010) Stefan A.J. Timmer et al.   NUCLEAR MEDICINE COMMUNICATIONS

Coronary microvascular resistance: methods for its quantification in humans

(2009) Paul Knaapen et al.   BASIC RESEARCH IN CARDIOLOGY

Impact of alcohol septal ablation on left anterior descending coronary artery blood flow in hypertrophic obstructive cardiomyopathy

(2009) Willem G. van Dockum et al.   INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING

Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathy

(2007) Paul Knaapen et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY